New analysis of the NOVA trial confirms clinical benefit from niraparib for patients with recurrent ovarian cancer. The benefit occurred both in patients with and in those without BRCA mutations.
Medscape Medical News
Original Article: TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer